文献速递膀胱癌与上尿路尿路上皮癌

全基因组CRISPR筛选揭示MSH2在肌层浸润性膀胱癌顺铂耐药中的作用

A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2018-11-07

该研究在膀胱癌细胞系中进行全基因组CRISPR筛选,发现MSH2是促进顺铂耐药的最显著富集基因,错配修复是最显著富集通路。MSH2敲低细胞顺铂诱导凋亡减少,且不影响奥沙利铂敏感性;MSH2蛋白低表达的膀胱肿瘤接受铂类化疗后生存更差。

要点

  • 全基因组CRISPR筛选鉴定MSH2为膀胱癌顺铂耐药的关键基因。
  • MSH2敲低减少顺铂诱导凋亡,但不影响奥沙利铂敏感性。
  • MSH2蛋白低表达与铂类化疗后生存更差相关,需前瞻性验证。

核心结论

  • 体外证据表明MSH2缺失的膀胱癌细胞对顺铂更耐药。
  • MSH2低表达的膀胱肿瘤患者接受铂类化疗后生存更差。
  • MSH2蛋白水平可能有助于筛选适合化疗的患者,但需前瞻性验证。

研究设计与样本

  • 在膀胱癌细胞系中进行全基因组CRISPR筛选以鉴定介导顺铂耐药的基因。
  • 在两个膀胱癌细胞系中进行靶向验证。
  • 在公开膀胱癌数据集中验证首要候选基因。

主要发现

  • CRISPR筛选中MSH2是最显著富集基因,错配修复是最显著富集通路。
  • MSH2敲低的膀胱癌细胞顺铂诱导凋亡减少。
  • MSH2缺失不影响包括奥沙利铂在内的其他化疗敏感性。
  • 反向蛋白阵列定量显示MSH2蛋白低的膀胱肿瘤接受顺铂或卡铂为基础治疗生存更差。

临床怎么用

  • MSH2蛋白水平有望作为预测铂类化疗反应的生物标志物,但需前瞻性临床试验验证。

局限性

  • MSH2蛋白低表达与生存的关联需未来用免疫组化验证。
  • 结果为回顾性分析,患者主要为高级别肿瘤。
  • 需在对照临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The response to first-line, platinum-based treatment of muscle-invasive bladder cancer has not improved in 3 decades. OBJECTIVE: To identify genes that influence cisplatin resistance in bladder cancer. DESIGN, SETTING, AND PARTICIPANTS: We performed a whole-genome CRISPR screen in a bladder cancer cell line to identify genes that mediate resistance to cisplatin. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Targeted validation was performed in two bladder cancer cell lines. The top gene candidate was validated in a publicly available bladder cancer dataset. RESULTS AND LIMITATIONS: From the CRISPR screen, we identified MSH2 as the most significantly enriched gene and mismatch repair as the most significantly enriched pathway that promoted resistance to cisplatin. Bladder cancer cells with knockdown of MSH2 showed a reduction in cisplatin-mediated apoptosis. MSH2 loss did not impact the sensitivity to other chemotherapies, including the cisplatin analog oxaliplatin. Bladder tumors with low MSH2 protein levels, quantified using reverse-phase protein array, showed poorer survival when treated with cisplatin- or carboplatin-based therapy; these results require future validation using immunohistochemistry. Additionally, results are retrospective from patients with primarily high-grade tumors; thus, validation in a controlled clinical trial is needed. CONCLUSIONS: We generated in vitro evidence that bladder cancer cell lines depleted of MSH2 are more resistant to cisplatin. We additionally found an association between low MSH2 in bladder tumors and poorer patient survival when treated with platinum-based chemotherapy. If successfully validated prospectively, MSH2 protein level could assist in the selection of patients for chemotherapy. PATIENT SUMMARY: We report the first evidence that MSH2 protein level may contribute to chemotherapy resistance observed in muscle-invasive bladder cancer. MSH2 has potential as a biomarker predictive of response to platinum-based therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Goodspeed A, Jean A, Costello JC, et al. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol. 2018. PMID: 30414698. doi:10.1016/j.eururo.2018.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。